Cordlife Group
P8AHealthcare (Diagnostics/Cord Blood Banking)Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test services. The company also provides corneal lenticule banking, and lifestyle genetic screening services for adults. In addition, it offers life sprouts, medical laboratory, marketing, and property investment services, as well as medical and pharmaceutical research and development and consulting services. Cordlife Group Limited was incorporated in 2001 and is based in Singapore.
Each figure shows where it came from. How we source our numbers →
Dividends
No upcoming ex-date announced yet.
Current-year dividends: S$0 per security
Pays Annual · 1 year of dividends on record, from 2022 onwards.
Full dividend history
| Ex-Date | Amount / Security |
|---|---|
| 06 May 2022 | S$0.009 |
Dividends by year
| Year | Total / Security | Yield* |
|---|---|---|
| 2022 | S$0.009 | 6.82% |
*Yield uses the current last price (S$0.132) against each year's total — indicative only.
Earnings
No earnings data yet for this counter.
Announcements & news
- SGX page for P8A ↗Price, trading data and this counter's own announcements
- SGX company announcements ↗Every counter's filings, if you need to search across them
- Investor relations ↗Cordlife Group's own results and presentations
- Latest news ↗Press coverage and commentary
Added via FTSE ST All-Share expansion research -- fundamentals not yet researched.
Price synced from SGX. Other figures carry their own source and date above. How we source our numbers